{"entity":{"id":"sequoia-pancreatic","kind":"trial","name":"SEQUOIA (pancreatic cancer)","aka":["SEQUOIA pegilodecakin","AM0010 phase 3"],"tldr":"SEQUOIA added the immune cytokine pegilodecakin to second-line FOLFOX chemotherapy for pancreatic cancer and found no gain in survival, progression or response, another negative test of immunotherapy in this cold tumour.","summary":"SEQUOIA randomised 567 patients between March 2017 and September 2019 (283 to pegilodecakin plus FOLFOX, 284 to FOLFOX), 94.7 percent of whom had received gemcitabine plus nab-paclitaxel. Median overall survival was 5.8 against 6.3 months (hazard ratio 1.045, 95 percent confidence interval 0.863 to 1.265), progression-free survival 2.1 months in both arms and response 4.6 against 5.6 percent. Thrombocytopenia (55 against 20 percent) and anaemia (40 against 16) were commoner with the cytokine while interleukin-18, interferon gamma and granzyme B rose as expected. Five UK sites took part (Addenbrooke's, Hammersmith, Velindre, University College London Hospitals, Guy's and St Thomas'). The FOLFOX control arm's 6.3 months is a useful benchmark for second-line chemotherapy in the gemcitabine-nab-paclitaxel era.","status":"negative","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02923921","url":"https://clinicaltrials.gov/study/NCT02923921"},{"label":"Hecht et al., SEQUOIA (JCO 2021)","url":"https://doi.org/10.1200/JCO.20.02232"}],"tags":[],"related":[],"cancers":["pancreatic","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["pegilodecakin","folfox"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":["cold-vs-hot","pancreatic-failed-programmes"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry, 5): Addenbrooke's Hospital Cambridge; Hammersmith Hospital; Velindre Hospital Cardiff; University College London Hospitals; Guy's and St Thomas'."],"nct":"NCT02923921","phase":"3","setting":"Metastatic pancreatic ductal adenocarcinoma progressing after one gemcitabine-containing regimen at sites in 13 countries: FOLFOX with or without pegilodecakin, with overall survival as the primary endpoint","sponsor":"Eli Lilly (ARMO BioSciences)","participation":[{"nct":"NCT02923921","source":"https://clinicaltrials.gov/study/NCT02923921","fetchedAt":"2026-11-17T07:29:35.741Z","studySha256":"89d576c1b57a92d259d4e924673d93d307858f0f6975bd94f40f73395136ccd5","responseStudySha256":"89d576c1b57a92d259d4e924673d93d307858f0f6975bd94f40f73395136ccd5","overallStatus":"COMPLETED","lastUpdatePosted":"2020-10-19","leadSponsor":"Eli Lilly and Company","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":567,"enrolmentType":"ACTUAL","siteCount":130,"recruitingSiteCount":0,"countries":["Australia","Austria","Belgium","Canada","France","Germany","Italy","Poland","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"result":"Median overall survival 5.8 months with pegilodecakin plus FOLFOX against 6.3 months with FOLFOX (hazard ratio 1.045, 95 percent confidence interval 0.863 to 1.265); progression-free survival 2.1 months in both arms.","started":"2017-03-01","startedType":"actual","yearReported":2021,"enrolled":567,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","unit":"months","arms":[{"name":"Pegilodecakin + FOLFOX","n":283,"value":5.8},{"name":"FOLFOX","n":284,"value":6.3}],"hr":1.045,"ci":[0.863,1.265],"source":"https://doi.org/10.1200/JCO.20.02232"}]},"route":"/trials/sequoia-pancreatic/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"pegilodecakin","kind":"drug","name":"Pegilodecakin","route":"/drugs/pegilodecakin/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}],"term":[{"id":"cold-vs-hot","kind":"term","name":"Hot vs cold tumours","route":"/terms/cold-vs-hot/"},{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/"}]}}